Abstract: AIM: To evaluate clinical efficacy and safety of seretide in the treatment of patients with mild to moderate asthma.Methods: This was an opened, self-comparison study.43 patients with mild to moderate asthma were given seretide 50 250 μg inhalation twice daily via accuhaler for 20 weeks.The levels of symptoms and signs before and after therapeutics were recorded as the quality of life.The peak expiratory flow (PEF), forced expiratory volume in one second(FEV₁), peak expiratory flow rate(PEFR), forced vital capacity(FVC) and symptomless time were detected.Results: The treatment with seretide resulted in remarkably improvement in efficacy variables of morning and evening PEF, asthma symptom scores.FEV₁ and FVC were notably increased after 1 week of treatment and during the treatment period (P<0.01).At the end of 20 weeks treatment, asthma quality of life scores were improved significantly (P<0.01).The amount of asymptomatic day of patients with mild to moderate asthma were increased.There were 39 patients achieving the criteria for well-controlled.Only 1 patient had hoarseness.Conclusion: Seretide possesses the advantage of effectiveness, safety and well tolerance in patients with mild to moderate asthma.

Key words: seretide, asthma, treatment, adverse effect